The Problem and Solution
Problem: Every year, 1.7 million patients in the United States develop a hospital-acquired infection. Nearly 99,000 of them will die. The annual cost to the healthcare system exceeds $28 billion.1 For 75 years, the standard of care has been to use ineffective antimicrobial solutions or to default to overuse of antibiotics. One creates a false sense of safety, while the other contributes to the global dilemna of rapidly expanding antibiotic resistance. The formula for PVP-I was invented in the 1950's and has significant downsides: it stains, it irritates, it's toxic when not used correctly and it delivers only 1–5 parts per million of actual biocidal iodine (molecular iodine). Above all, the majority of it's ingredients are essentially filler and provide zero antimicrobial benefit.
Solution: At I2Pure, we've focused on the only biocidal agent within PVP-I - the naturally-occurring, non-toxic molecule "molecular iodine". This is the only form of iodine that actually kills pathogens. I2Pure scientists have established the protocols necessary to harness molecular iodine, enabling it to be integrated into new products and those already on the market. Our research and resulting patents, serve to clarify the nature of molecular iodine and dispelled misconceptions that have inhibited more effective use of this naturally-occurring biocide.
Through our research and work, we know molecular iodine is the key to reducing the grip, resulting costs and lethality of pathogens.
Who We Are and What We're About
I2Pure is an iodine technology company dedicated to advancing the world of health and biosafety by preventing infections and disease through its patented, non-toxic molecular iodine platform.
Our chemistry supercharges antisepsis across virtually every facet of surgical and therapeutic interaction with human or animal tissue to prevent infection.
I2Pure technology can be delivered via solutions, polymers and coatings and can be extended into medical devices, antisepsis, cosmetics, water safety, food safety and preservation, aquaculture and more.
The Science, Simply Put.
Molecular iodine — I2 — is produced naturally by every vertebrate on earth, including humans. It penetrates pathogen cell walls, disrupts DNA synthesis, and destroys pathogenic organisms completely while leaving healthy cells unaffected. No pathogen has ever evolved a resistance to it.
I2Pure has patented the process of stabilizing molecular iodine at concentrations up to 15,000 ppm without the need for other iodine species. With this chemistry in hand, we've developed the expertise necessary to accomodate the uniqueness of molecular iodine and how it can be formulated into a wide variety materials (such as tubing and wound treatments), liquids (such as lotions) and sanitation solutions (such as industrial clean in place).
The Proof
I2Pure’s bio-technology has been validated independently — by some of the leading research institutions across North America. I2Pure's molecular iodine formulations are non-toxic, biocompatible and effective against a broad spectrum of bacteria and viruses. They can be integrated within a variety of products from topical OTC to medical devices to water and food treatment.
I2Pure executes its first license - a perpetual global license to a leading multinational healthcare company. The platform built over six years is now scaling and available to OTC and healthcare sectors for immediate availability.
I2Pure relocated into a larger facility with additional manufacturing capacity and meeting room space.
Led by Doctors Bayer and Kessler, the I2Pure science team documented the impact of carrier polymers and phospholipids on release and transport of molecular iodine across biologically relevant interfaces.
View Paper: Transport of Molecular Iodine From Antiseptic Iodophors across Hydrophilic–lipophilic Interfaces: Influence of Phospholipids
I2Pure launches an online store at i2Results.com where multiple products are available - hand sanitizers, antiseptic gel, skin serum, acne treatment and nasal decolonization.
Doctors Kessler & Hooper publish human skin explant data confirming I2 safety at 500–15,000 ppm across 24-hour exposures, with active biofilm eradication demonstrated. The most comprehensive independent safety dataset on molecular iodine ever published.
View Paper: Topical Molecular Iodine - An Optimal Biocide Constrained by Inadequate Formulations.
This facility supports our efforts to develop novel formulations and techniques for applying molecular iodine to or integrating molecular iodine within a wide-ranging scope of products from healthcare and veterinary care to water disinfection and industrial cleaning applications.
Dr. Bayer came to I2Pure from the Istituto Italiano di Tecnologia (iit) where he had been a research scientist since 2010. Dr. Bayer received his Ph.D. degree in surface engineering from the Department of Mechanical Engineering at the University of Illinois and was a visiting professor at the Department of Mechanical and Aerospace Engineering of the University of Virginia.
I2Pure, known for its expertise in iodine science and innovation, has developed a novel and proprietary methodology to infuse nano particles with iodine that results in shelf-stable, pH-neutral iodine solutions. Using this technology, the efficacy of existing iodine products can be improved, and new iodine products can be developed that were previously out-of-reach to science and medicine.
The new Chief Executive Officer, Jeffrey Jochims, joins I2Pure effective November 1, 2023. Jochims assumes this role following more than 25 years of leadership in the life sciences and healthcare industries, including long executive tenures at industry leaders Thermo Fisher Scientific and Owens & Minor. In addition, Jochims has deep experience in entrepreneurial start-ups as well as global life sciences and healthcare companies of all sizes.
Sociedad Química y Minera de Chile (SQM) — the world’s largest iodine producer — awards I2Pure an Innovation Grant to fund independent safety and efficacy research.
Freeman, Duan & Kessler publish peer-reviewed research confirming that molecular iodine is not responsible for the cytotoxicity and staining attributed to traditional iodine formulations. The scientific case for I2Pure’s approach is independently validated in one of the field’s most respected journals.
This competition is designed to recognize Loudoun County Virginia local companies that are rethinking the status quo in their industries. I2Pure took the Tech Venture category top spot. This year had an enormous amount of competition with a total of 156 applicants. I2Pure was thrilled to have stood out among so many inventive and forward-thinking businesses.
I2Pure Inc. is established to commercialize the molecular iodine stabilization technology developed by the founding scientific team. The founding thesis: a problem that has constrained iodine antiseptics for 75+ years is a formulation problem — and it is solvable.
Where Does Your Interest Lie?
